Capricor TherapeuticsNASDAQ: CAPR

--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) on next steps for the Biologics License Application (BLA) submission with its lead asset, CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Additionally, Deramiocel has been selected as the proposed International Nonproprietary Name (INN) for CAP-1002 by the World Health Organization.

Capricor Therapeutics, Inc. held its Q1 2024 Earnings Call on May 13, 2024 at 4:30 PM ET. The call featured CFO AJ Bergmann and CEO Linda Marban, with participants from Cantor Fitzgerald, Piper Sandler, H.C. Wainwright, and Ladenburg Thalmann & Co. Welcome to all attendees joining the call.

Capricor Therapeutics (CAPR) reported a quarterly loss of $0.31 per share, which was higher than the expected loss of $0.11 per share according to the Zacks Consensus Estimate. This is the same loss per share as reported a year ago.

The average price target set by analysts on Wall Street suggests a potential increase of 218.2% in Capricor. Although the reliability of this metric is uncertain, the positive trend in earnings estimates could lead to a rise in the stock.

The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2023 Financial Results and Corporate Update Call.

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.